Investigating Amphoteric 3,4′-Biscoumarin-Based ortho-[(Dialkylamino)methyl]phenols as Dual MAO and ChE Inhibitors
International Journal of Molecular Sciences · 20.10.2025 · 26 (20) · 10197
DOI: 10.3390/ijms262010197 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.10.2025. Verfasst von Anthi Petrou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. Hauptthemen laut MEDLINE: Monoamine Oxidase Inhibitors, Monoamine Oxidase, Cholinesterase Inhibitors, Coumarins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Nineteen previously and newly synthesized amphoteric 8-[(dialkylamino)methyl]-7-hydroxy-4-(2-oxo-2H-chromen-3-yl)-2H-chromen-2-ones were assayed as inhibitors of monoamine oxidases (MAO-A and B) and cholinesterases (AChE and BChE). Five of the tested compounds (2b, 2c, 3c, 5b, and 5c), namely those bearing the less bulky alkyls in the Mannich base 8-CH2NR2 (R = Me, Et) and the halogens (Cl, Br) at C6 of the 4-coumarin-3-yl moiety, showed moderate inhibitory potencies toward human MAO-A in the single-digit micromolar range (IC50s from 1.49 to 3.04 µM). In particular, the 6′-Cl derivatives 2b and 5b proved to be reversible competitive inhibitors of human MAO-A with Ki values of 0.272 and 0.326 µM. Among the tested compounds, 3c proved to also be a moderate inhibitor of human AChE (IC50 4.27 µM). Molecular docking calculations suggested binding modes of the most active compounds to MAO-A and AChE binding sites consistent enough with the experimental data. Chemoinformatic tools suggest for the most active compounds, including the dual MAO-A/AChE inhibitor 3c, full compliance with Lipinski’s rule of five, high probability of gastrointestinal absorption, but low blood–brain barrier (BBB) permeability. While further efforts are required to improve their CNS distribution, herein new phenolic Mannich bases have been identified that may have potential for treating neurodegenerative syndromes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
- Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, Via E. Orabona 4, 70125 Bari, Italy.
- Zelinsky Institute of Organic Chemistry, Leninsky Prospect, 119991 Moscow, Russia.
- InterBioScreen Ltd., 119019 Moscow, Russia.
ORCID-Profile: Anthi Petrou, Caterina Deruvo, Rosa Purgatorio, Boris Lichitsky, Andrey N Komogortsev, Modesto de Candia, Marco Catto, Cosimo D Altomare, Athina Geronikaki
Zitieren
APA
Petrou, A., Deruvo, C., Purgatorio, R., Lichitsky, B., Komogortsev, A. N., Kartsev, V. G., de Candia, M., Catto, M., Altomare, C. D., & Geronikaki, A. (2025). Investigating Amphoteric 3,4′-Biscoumarin-Based ortho-[(Dialkylamino)methyl]phenols as Dual MAO and ChE Inhibitors. International Journal of Molecular Sciences, 26(20), 10197. https://doi.org/10.3390/ijms262010197
Vancouver
Petrou A, Deruvo C, Purgatorio R, Lichitsky B, Komogortsev AN, Kartsev VG, et al. Investigating Amphoteric 3,4′-Biscoumarin-Based ortho-[(Dialkylamino)methyl]phenols as Dual MAO and ChE Inhibitors. International Journal of Molecular Sciences. 2025;26(20):10197. doi:10.3390/ijms262010197
BibTeX
@article{Petrou2025,
author = {Petrou, Anthi and Deruvo, Caterina and Purgatorio, Rosa and Lichitsky, Boris and Komogortsev, Andrey N and Kartsev, Victor G and de Candia, Modesto and Catto, Marco and Altomare, Cosimo D and Geronikaki, Athina},
title = {Investigating Amphoteric 3,4′-Biscoumarin-Based ortho-[(Dialkylamino)methyl]phenols as Dual MAO and ChE Inhibitors},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {20},
pages = {10197},
doi = {10.3390/ijms262010197}
}
EUVIMED